Brain

Tumor Perfusion: Correct the Leak Before You Trust the Map

Fellowship-level neuroradiology teaching by E. Brooke Schrickel, MD. Open this topic in the interactive reading room →

Watch · concise explainerCorrect the leak, then read CBV

Core clinical idea

Leaky lesions corrupt the CBV map, so before trusting any perfusion number you must know whether leakage was corrected — an uncorrected map can turn radiation necrosis into a 'high-CBV recurrence' and send a patient to unnecessary surgery. Used correctly, CBV and K-trans answer the two questions conventional MR can't: how aggressive is the tumor, and is post-treatment enhancement real tumor or treatment effect.

Bottom line

Don't trust a CBV map until leakage is corrected — then high CBV means aggressive/recurrence, low CBV means treatment effect, and FLAIR catches the pseudoresponse.

Core workstation questions

Was leakage corrected or a preload given before I trust this CBV value?
In a treated bed, is CBV genuinely elevated (recurrence) or low (radiation necrosis/pseudo-progression)?
On anti-angiogenic therapy, is falling enhancement real response or pseudo-response — what is FLAIR doing?
Does perfusion disagree with a low-grade biopsy result (sampling error)?
Is there nodular, subependymal, or leptomeningeal enhancement arguing for true progression?

What changes reporting / management

When CBV looks high in a treated bed, state whether leakage correction was applied before calling recurrence.
Point biopsy/resection at the highest-CBV region, and don't be reassured by a low-grade path result if perfusion says otherwise (sampling error).
New enhancement without rising perfusion favors treatment effect over progression — can spare a therapy change or operation.
Suggested phrasing: decreased enhancement and perfusion in the setting of anti-angiogenic therapy; however, increasing FLAIR signal abnormality suggests non-enhancing tumor progression (pseudoresponse).
Flag nodular/subependymal or leptomeningeal enhancement as tumor spread favoring true progression.

Practical traps

Reading an uncorrected CBV map at face value — radiation necrosis can masquerade as high-CBV recurrent tumor and prompt surgery on a non-tumor.
Treating falling enhancement/CBV on bevacizumab as response when it is pseudoresponse from vessel normalization, not cell kill.
Trusting a single biopsy over perfusion when CBV indicates a higher grade than sampled.
Ignoring FLAIR/non-enhancing growth in the treated brain.

Teaching pearls

Correct for leakage before you trust CBV — uncorrected, radiation necrosis can look like recurrence.
If two CBV maps disagree, suspect the leakage handling, not the tumor.
High CBV beats a single biopsy spot — perfusion can catch the undersampled high grade.
New enhancement without rising perfusion favors treatment effect, not progression.
On bevacizumab, falling enhancement/CBV may be pseudoresponse — read the FLAIR.

Source lectures

Perfusion and Permeability Imaging in Brain Tumors

Educational material for radiology residents and neuroradiology fellows. Nothing here drives individual patient care, and it contains no patient data.